The Cicada COVID-19 variant, an offshoot of the Omicron family, has emerged as a new concern in India. First spotted in South Africa in November 2024, it carries over 70 mutations compared to the original Wuhan strain, with around 50 of those located in the spike protein.
As of now, the variant has been detected in 22 countries, including India, where health officials are closely monitoring its spread. Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash.
Despite its extensive mutations, the Cicada variant is not confirmed to cause more severe illness than previous variants. This has led to some cautious optimism among health experts, though the situation remains fluid.
Dr. Robert Hopkins Jr. noted, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This statement underscores the uncertainty surrounding the variant’s potential impact.
The first confirmed case of the Cicada variant in the United States was reported in June 2025, with three patients confirmed by January 2026, all of whom recovered. This timeline highlights the variant’s rapid spread across borders.
Monitoring the spread of BA.3.2, as the Cicada variant is classified, is crucial. The CDC emphasized that it provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from previous infections or vaccinations.
Details remain unconfirmed regarding the real-world data on the severity of illness caused by the Cicada variant. As health officials in India and around the world continue to assess the situation, the focus remains on understanding the implications of this new variant.
As the pandemic evolves, the emergence of the Cicada variant serves as a reminder of the ongoing challenges posed by COVID-19. Vigilance and adaptability in public health responses will be essential in managing its spread.
